Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Fiskus W, Mill CP, Bose P, Masarova L, et al. Blood 2025;145:612-624.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fiskus W, Mill CP, Bose P, Masarova L, et al. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood 2025;145:612-624.
PMID: 39561280